Poland· PL-100010567

Bioracef

A cefuroxime product containing cefuroximum, registered in Poland by Zakłady Farmaceutyczne POLPHARMA S.A.. The same ATC class is registered in 15 of our 19 countries.

ATC J01DC02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBioracefATCJ01DC02REGISTER NO.PL-100010567PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Cefuroxime is registered in 15 of 19 countries.

Countries holding a registration under ATC J01DC02 (cefuroxime), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Cefuroxime · ATC J01DC02

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cefuroxime costs, country by country.

Normalised to the WHO defined daily dose (0.5 g), the median price runs from $0.0038 in Finland to $4.41 in Switzerland — a ×1160 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Cefuroxime · price per daily dose (0.5 g)

USD · FX 28 Sept 2026

  • CH Switzerland$4.41
  • IT Italy$1.06
  • FI Finland$0.0038
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Cefuroximum
Manufacturer
Zakłady Farmaceutyczne POLPHARMA S.A.
Country
Poland (PL)
ATC code
J01DC02
ATC class
Cefuroxime
Defined daily dose
0.5 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

2 priced
  • gtin
    05909990063840
    10 szt.
    PLN 30.92
  • gtin
    05909990063857
    14 szt.
    PLN 39.54
  • gtin
    05909990360611
  • gtin
    05909990360628

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

210 interactions on record for cefuroxime.

Graded by severity as the source publishes them — 46 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cefuroxime · interactions on record

210 records

  • 46 moderate
  • 164 info

Most severe, free to view

  • Magnesium carbonateA02AA01moderate
  • Magnesium oxideA02AA02moderate
  • Magnesium hydroxideA02AA04moderate
  • Kombinationen von AluminiumsalzenA02AB10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cefuroxime in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cefuroxime products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Aprokam, Cefuroxim Aptapharma
  • Belgium · Aprokam, Cefuroxim Fresenius Kabi
  • Bulgaria · Аксетин, Аксеф
  • Cyprus · Axetine, Cefurax
  • Czechia · Aprokam, Axetine
  • Germany · Aprokam, Cefurax
  • Denmark · Aprokam, Cefuroxim B. Braun
  • Estonia · Axetine, Cefuroxime Mip
  • Spain · Cefuroxima Alter, Cefuroxima Cinfa
  • Finland · Aprokam, Cefirion
  • France · Aprokam, Cefuroxime Arrow
  • United Kingdom (Northern Ireland) · Aprokam, Cefuroxime
  • Greece · Anaptivan, Cefur
  • Croatia · Axetine, Beloxim
  • Hungary · Cefuroxim Kabi, Cefuroxime Aptapharma
  • Ireland · Aprok, Ceftal
  • Iceland · Aprokam, Cefuroxim Fresenius Kabi
  • Italy · Aprokam, Cefuroxima K24 Pharmaceuticals
  • Lithuania · Axetine, Cefuroxime Mip
  • Luxembourg · Aprokam, Cefuroxim Fresenius
  • Latvia · Axetine, Cefuroxime Bcpp
  • Malta · Axetine, Cefuroxime Axetil Ccav
  • Netherlands · Aprokam, Cefuroxim Fresenius Kabi
  • Norway · Aprokam, Cefuroxim B. Braun
  • Portugal · Antibioxime, Aprokam
  • Romania · Aprokam, Axetine
  • Sweden · Aprokam, Cefuroxim Mip
  • Slovenia · Aprokam, Cefuroksim Aptapharma
  • Slovakia · Aprokam, Axetine

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d0a992fe-c984-4055-b730-2aa6778670b4
GET /v1/drugs/d0a992fe-c984-4055-b730-2aa6778670b4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "250 mg",
  "packaging": "05909990360611 ¦ Rp ¦ 1953\n10 tabl. w pojemniku\n05909990360628 ¦ Rp ¦ 11240\n14 tabl. w pojemniku\n05909990063840 ¦ Rp ¦ 37111\n10 tabl. w blistrach\n05909990063857 ¦ Rp ¦ 37112\n14 tabl. w blistrach",
  "substance": "Cefuroximum axetilum 250 mg",
  "common_name": "Cefuroximum",
  "pl_product_id": "100010567",
  "pozwolenie_nr": "03606",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about cefuroxime.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.